Top Markets
#1 Pleasing Gold Pleasing Gold +1,557.08%
#2 PulseChain PulseChain +55.72%
#3 DogBull DogBull +37.22%
#4 Ontology Gas Ontology Gas +35.76%
#5 BOOK OF MEME BOOK OF MEME +31.40%
#6 Collect on Fanable Collect on Fanable +24.33%
#7 Neiro Neiro +20.73%
#8 Pump.fun Pump.fun +18.66%
#9 Unit Pump Unit Pump +18.66%
#10 Cryptopia Cryptopia +17.74%
Coin of the day
Pleasing Gold Pleasing Gold
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Cytocom, Inc. Cytocom, Inc.

Cytocom, Inc.

CBLI
Hisse Senetlerindeki Sıralama #27147
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in... Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Hisse Fiyatı
$3.17
Son senkronizasyon: 2021-08-31
Piyasa Değeri
$34.83M
Değişim (1 gün)
-7.31%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Cytocom, Inc. (CBLI)

Kategori

Healthcare
Cytocom, Inc. (CBLI) için kazanç
2026 itibarıyla kazanç TTM: 0
Cytocom, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Cytocom, Inc. için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH